Aprea

Aprea Therapeutics is a clinical-stage biopharmaceutical company developing synthetic lethality-based cancer therapeutics targeting DNA damage response pathways, based in Doylestown, Pennsylvania, United States. Operating with a dedicated clinical team of eight employees, the pre-revenue enterprise focuses on advancing precision oncology treatments for patients with genetically defined solid tumors and hematologic malignancies. The publicly traded biotechnology firm successfully raised $85 million during its 2019 initial public offering on the NASDAQ exchange, and it has received historical backing from institutional investors including 5AM Ventures, Versant Ventures, and Karolinska Development. To expand its clinical pipeline of targeted inhibitors, the organization acquired Atrin Pharmaceuticals in late 2021 and it recently secured FDA clearance for its lead WEE1 kinase inhibitor candidate, APR-1051. Aprea Therapeutics was originally founded in 2002 by Karolinska Institute researchers Klas Wiman, Galina Selivanova, and Vladimir Bykov.